Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.
Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K, Socci ND, Lailler N, Heguy A, Dolgalev I, Migliacci JC, Pirun M, Palomba ML, Weinstock DM, Wendel HG. Schatz JH, et al. Among authors: palomba ml. Leukemia. 2015 Jan;29(1):237-41. doi: 10.1038/leu.2014.261. Epub 2014 Sep 3. Leukemia. 2015. PMID: 25257991 Free PMC article. No abstract available.
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.
Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, Palomba MLM, Portlock C, Straus DJ, Noy A, Horwitz SM, Moskowitz A, Hamlin P, Moskowitz CH, Matasar MJ, Zelenetz AD, Younes A. Kumar A, et al. Blood Cancer J. 2019 May 20;9(6):50. doi: 10.1038/s41408-019-0209-5. Blood Cancer J. 2019. PMID: 31110172 Free PMC article.
Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue.
Kumar A, Bantilan KS, Jacob AP, Park A, Schoninger SF, Sauter C, Ulaner GA, Casulo C, Faham M, Kong KA, Grewal RK, Gerecitano J, Hamilton A, Hamlin P, Matasar M, Moskowitz CH, Noy A, Palomba ML, Portlock CS, Younes A, Willis T, Zelenetz AD. Kumar A, et al. Among authors: palomba ml. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):230-237.e12. doi: 10.1016/j.clml.2020.09.007. Epub 2021 Jan 1. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33558202 Free PMC article.
Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma.
Luan D, DeWolf S, Fei T, Raj S, Shah GL, Lareau CA, Alhomoud M, Salles G, Rivas-Delgado A, Rejeski K, Park JH, Luttwak E, Luna de Abia A, Corona M, Ntrivalas E, Cassanello G, Gomez-Llobell M, Parascondola A, Scordo M, Hsu KC, Palomba ML, Perales MA, Shouval R. Luan D, et al. Among authors: palomba ml. Blood Cancer Discov. 2024 Dec 12. doi: 10.1158/2643-3230.BCD-24-0163. Online ahead of print. Blood Cancer Discov. 2024. PMID: 39666878
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Capadona C, Subzwari S, Galasso N, Yang J, Post M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Salles GA, Steiner R, Stuver R, Vardhana S, Yahalom J, Dogan A, Zelenetz AD, Schöder H, Moskowitz AJ. Torka P, et al. Among authors: palomba ml. J Clin Oncol. 2024 Dec 11:JCO2401278. doi: 10.1200/JCO-24-01278. Online ahead of print. J Clin Oncol. 2024. PMID: 39661923
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.
Boardman AP, Gutgarts V, Flynn J, Devlin SM, Goldman A, Tomas AA, Fein JA, Slingerland JB, Parascondola A, Lin RJ, Scordo M, Dahi PB, Giralt S, Palomba ML, Salles G, Nath K, Walji M, Corona M, Park JH, Shah GL, Perales MA, Jaffer-Sathick I, Shouval R. Boardman AP, et al. Among authors: palomba ml. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286021. Online ahead of print. Haematologica. 2024. PMID: 39568416 Free article.
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes.
Valtis YK, Devlin S, Shouval R, Rejeski K, Corona M, Luna De Abia A, Rivas-Delgado A, Luttwak E, Cassanello G, Landego I, Schöder H, Bedmutha A, Boardman A, Shah GL, Scordo M, Perales MA, Salles G, Palomba ML, Shah UA, Park JH. Valtis YK, et al. Among authors: palomba ml. Blood Adv. 2025 Jan 14;9(1):151-161. doi: 10.1182/bloodadvances.2024014555. Blood Adv. 2025. PMID: 39471490
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.
Melica G, Luna de Abia A, Shah GL, Devlin S, Corona M, Fein J, Dahi PB, Giralt SA, Lin RJ, Palomba ML, Parascondola A, Park J, Salles G, Saldia A, Scordo M, Shouval R, Perales MA, Seo SK. Melica G, et al. Among authors: palomba ml. Transplant Cell Ther. 2024 Oct 22:S2666-6367(24)00727-9. doi: 10.1016/j.jtct.2024.10.010. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39448032 Free article.
131 results